Looking back at developments in antithrombotic prophylaxis, focusing on the past 25 years

Czech version

Authors: M. Penka; M. Matýšková; J. Michalcová
Authors‘ workplace: Oddělení klinické hematologie Fakultní nemocnice Brno
Published in: Transfuze Hematol. dnes,25, 2019, No. 1, p. 56-64.
Category: Review/Educational Papers

Overview

As in other fields, the past 25 years have seen concentrated research in the area of drugs that reduce blood clotting-antithrombotics. Their purposeful application dates to the early 20th century and the past 25 years have seen intense acceleration of this interest. These drugs include not only classical products, but mainly new targeted drugs affecting blood clotting at specific sites. These represent the group of novel or direct anticoagulants (NOACs or DOACs).

Keywords:

NOAC – dabigatran – antithrombotics – Anticoagulants – unfractionated heparin (UFH) – low molecular weight heparin (LMWH) – warfarin – laboratory monitoring

Sources

1. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008;141: 757–763.

2. Shampo MA, Kyle ARJ. Erik Jorpes – pioneer in the identification and clinical applications ofh. Mayo Clin Proc 1997;72:1056.

3. Markwardt F. Historical perspective of the development of thrombin inhibitors. Pathophysiol Haemost Thromb 2002;32(suppl 3):15–22.

4. Bauer KA, Hawkins PCP, Petitou M, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents – the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002;20(1): 37–52.

5. Yeh CH, Fredenburgh JC, Weitz JI. Oral direct factor Xa inhibitors. Circ Res 2012;111:1069–1078.

6. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease. CHEST Guideline and Expert Panel Report. CHEST 2016;149(2):315–352.

7. Barnes GD, Ageno W, Ansell J, Kaatz S. For the subcommittee on the control of anticoagulation. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 2015;13(6):1154–1156.

8. Nutescu EA, Burnett A, Fanikos J, et al. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016;41:15–31.

9. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin, Thromb Haemost 2008;99:819–829.

10. Escolar G, Bozzo J, Maragall S. Argatroban: A direct thrombin inhibitor with reliable and predictable anticoagulant actions. Drugs Today 2006;42(4):223.

11. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988;208:227–240.

12. Bergqvist D. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery. Br J Surg 2004;91:965–974.

13. Bultas J, Karetová D. Antitrombotika v prevenci cévní mozkové příhody, 2. Část – význam antikoagulační léčby. Kardiol Rev 2013;15(1):41–53.

14. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263–272.

15. The European Medicines Agency. Souhrn údajů o přípravku Arixtra. [online]. Dostupné na www: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000403/WC500027746.pdf.

16. The European Medicines Agency. Souhrn údajů o přípravku Pradaxa. [online]. Dostupné na www: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf>.

17. The European Medicines Agency. Souhrn údajů o přípravku Eliquis. [online]. Dostupné na www: <http://www.ema.europa.eu/docs/cs_CZ/document_librar/EPAR_-_Product_Information/human/002148/WC500107728.pdf >.

18. The European Medicines Agency. Souhrn údajů o přípravku Xarelto. [online]. Dostupné na www: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf>.

19. The European Medicines Agency. Souhrn údajů o přípravku Lixiana. [online]. Dostupné z: <https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_cs.pdf>

20. Junqueira DR, Perini E, Penholati RR, Carvalho MG. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 2012;(9):CD007557 doi: 10.1002/14651858.CD007557.pub2.

21. Matýšková M. Warfarin, potrava a potravinové doplňky. Interní Med 2010;12(2):87–91.

22. Kvasnička J, Hájková J, Bobčíková P, et al. Prevalence polymorfismů CYP2C9 a VKORC1 v České republice a zamyšlení nad výhledy antikoagulační léčby warfarinem. Cor et Vasa, Epstein et al., JACC 2010;55: 280.

23. Heparin-leciva-spc.pdf. Dostupné na www: http://www.sukl.cz/modules/medication/detail.php?code=0091915&tab=texts.

24. Fitzmaurice DA, Blann AD, Lip GYH. Bleeding risks of antithrombotic therapy. BMJ 2002;325(7368):828–831.

25. Baglin T, Barrowcliffe TW, Cohen A, Greaves M. for the British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin. Br J Haematol 2006;133:19–34 doi:10.1111/j.1365-2141.2005.05953.x.

26. Samuelson BT, Cuker A, Siegal DM, et al. Laboratory assessment of the anticoagulant aktivity of direct oral anticoagulants. Chest 2017;151(1):127–138 http://dx.doi.org/10.1016/j.chest.2016.08.1462.

27. Salmonson T, Dogné J-M, Janssen H, et al. Non-vitamin-Koral anticoagulants and laboratory testing: now and in the future. Views from a workshop at the European Medicines Agency (EMA). Europ Heart J – Cardiovasc Pharmacoth 2017;3:42–47 doi:10.1093/ehjcvp/pvw032.

28. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort Aanalysis. N Engl J Med 2017;377:431–441 DOI: 10.1056/NEJMoa1707278.

29. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413–2424 DOI: 10.1056/NEJMoa1510991.

30. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vascular Health Risk Management 2016;12:35–44 https://doi.org/10.2147/VHRM.S89130.

31. Nielsen PB, Skjøth F, Søgaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017;356:j510 doi: 10.1136/bmj.j510.

32. Michalcová J, Penka, M, Buliková A, et al. Nová – přímá perorální antikoagulancia: aktuální přehled. Vnitr Lek 2016;62(10):805–813.

33. Robertson L, KestevenP, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews 2015;6: Art. No.:CD010956 DOI: 10.1002/14651858.CD010956.pub2..

34. Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS ONE 2015;10(12):e0144856 doi.org/10.1371/journal.pone.0144856.

35. Kvasnička J, Penka M, Kvasnička T, et al. Doporučení České společnosti pro trombózu a hemostázu České lékařské společnosti
J. E. Purkyně pro bezpečnou léčbu novými perorálními antikoagulancii (NOAC) – dabigatran etexilátem, apixabanem a rivaroxabanem. Vnitr Lek 2015;61(6):537–546.